Management of bleeding in patients using antithrombotic agents: Prediction, prevention, protection and problem-oriented intervention

Hamostaseologie

Volumn 29, Issue 4, 2009, Pages 388-398

  Scharf, Rüdiger E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Antiplatelet drugs; Clinical trials; Coagulation factor concentrates; Haemostasis monitoring; Platelet transfusions; Vitamin K antagonists

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; APROTININ; ARGATROBAN; BETRIXABAN; BROMAZEPAM; CANGRELOR; CLOPIDOGREL; DESMOPRESSIN; DIBIGATRAN ETIXILATE; EDOXANBAN; EPTIFIBATIDE; ERIBAXABAN; HIRULOG; LEPIRUDIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PRASUGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TICAGRELOR; TIROFIBAN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INCIDENCE; LIVER CIRRHOSIS; PERIOPERATIVE PERIOD; PREDICTION; REVIEW; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 70549096980     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617135     Document Type: Review

References (63)

1. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; 4: CD001925.
2. Ahrens I, Schwarz M, Peter K, Bode C. Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers. Transf Med Hemother 2007; 34: 44-54. (Pubitemid 46173546)
3. Alban S. Pharmacology of heparins and direct anticoagulants. Hämostaseologie 2008; 28: 400-420.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
5. Antithrombotic Trialists' Collaboration, Baigent C, Blackwell L, Collins R et al. Asprin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
6. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA Guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: E1-E211.
7. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28.
8. Braunwald E, Antman E, Beasley J et al. ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002. Circulation 2002; 106: 1893-1900.
9. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49: 2145-2150. (Pubitemid 46824115)
10. Budde U, Scharf RE, Franke P et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1994; 82: 475-482.
11. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004; 126: 401S-428S.
12. Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulaant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
13. Cattaneo M. New P2Y12 blockers. J Thromb Haemost 2009; 7(Suppl 1): 262-265.
14. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621. (Pubitemid 41552416)
15. Coller BS. Anti-GPIIb-IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-443. (Pubitemid 32663972)
16. Crowther MA, Ginsberg JS, Hirsh J. Practical aspects of anticoagulant therapy. In: Colman RW, Hirsh J, Marder VJ et al. (eds). Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams & Wilkins 2004: 1497-1516.
17. Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782. (Pubitemid 44268228)
18. Eikelboom, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 2007; 5 (Suppl 1): 255-263.
19. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Inter Med 2004; 141: 745-752. (Pubitemid 39524912)
20. Fuster V, Ryden LE, Cannon DS et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: c257-c354.
21. Gage BF, van Walraven C, Pearce L et al. Selecting patients with artrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292. (Pubitemid 39407328)
22. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
23. Gitter MJ, Jaeger TM, Petterson TM, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733.
24. Greaves M, Watson HG. Approach to the diagnosis and management of mild bleeding disorders. J Thromb Haemost 2007; 5 (Suppl 1): 167-174. (Pubitemid 46958830)
25. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation 2006; 113: e463-e654.
26. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
27. Joist JH, George JN. Hemostatic abnormalities in liver and renal disease. In: Colman RW, Hirsh J, Marder VJ et al. (eds). Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams & Wilkins, 2004: 955-973.
28. Langer E, Zimmer S. Established anticoagulants in secondary hemostasis. Hämostaseologie 2009; 29: 241-246.
29. Levi M, Hovingh GK, Cannegieter SC et al. Bleeding in patients receiving vitamin K antagonists who would hve been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471-4476.
30. Levi M. Epidemiology and management of bleeding in patients using vitamin K antagonists. J Thromb Haemost 2009; 7 (Suppl 1): 103-106.
31. Mangano DT, Miao, Vuylsteke A et al. Mortality associated with aprotinin during five years following coronary artery bypass graft surgery. JAMA 2007; 297: 527-529.
32. Mannuci PM. Desmopressin in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521. (Pubitemid 27413458)
33. May AE, Geisler T, Gawaz MP. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
34. Mellemkjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181. (Pubitemid 34264272)
35. Patrono C, Coller BS, FitzGerald GA et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 2004; 126: 234S-264S.
36. Perzborn E. Factor Xa inhibitors. New anticoagulants for secondary hemostasis. Hämostaseologie 2009; 29: 260-267.
37. Pötzsch B, Scharf RE. Hemostasis-navigated hemotherapy, diagnosis, management, and monitoring of patients with active bleeding. In: Scharf RE (ed). Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. Freiburg: Karger 2008: 385-393.
38. Porter A, Konstantino Y, Iakobishvili Z et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 56-61. (Pubitemid 44024462)
39. Ridell JW, Chiche L, Plaud B, Hamon M. Coronary stents and noncardiac surgery. Circulation 2007; 116: e378-e382.
40. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet 2005; 365: 82-93.
41. Sabatine MS, Cannon CP, Gibson CM et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolysic therapy for myorcardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
42. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Circulation 2006; 113: e409-e449.
43. Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 323-325. (Pubitemid 36886236)
44. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432. (Pubitemid 20059511)
45. Scharf RE. Thrombozyten und Mikrozirkulationsstörungen. Klinische und experimentelle Untersuchungen zum Sekretionsverhalten und Arachidonsäurestoffwechsel der Blutplättchen. Stuttgart: Schattauer 1986.
46. Scharf RE. In vitro thromboxane synthesis of depleted platelets following renal transplantation. Thromb Haemost 1990; 64: 161-164.
47. Scharf RE. Congenital and acquired platelet function disorders. Hämostaseologie 2003; 23: 170-180.
48. Scharf RE. Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, and clinical management. Hämostaseologie 2008; 28: 299-311.
49. Scharf RE. Acquired platelet function defects: an underestimated but frequent cause of bleeding complications in clinical practice. In: Scharf RE (ed). Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. Freiburg: Karger 2008: 296-316.
50. Scharf RE, Hoffmann T, Kirchhoff EM, Kelm M. Unpublished observations 2009.
51. Scharf RE, Hoffmann T. Unpublished observations 2009.
52. Schrör K, Hohlfeld T. Acetylsalicylic acid. Weinheim: Wiley VCH, 2009: 94.
53. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 257S-298S. (Pubitemid 351892969)
54. Serebruany VL, Malin AI, Ferguson JJ et al. Bleeding risks of combination versus single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008; 22: 315-321.
55. Spivak JL. Polycythemia vera and other myeloproliferative diseases. In: Kasper DL, Braunwald E, Fauci AS et al. (eds). Harrison's Principles of Internal Medicine. New York: McGraw-Hill 2005: 626-631.
56. Steering Commiittee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
57. Sucker C, Feindt P, Scharf RE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 1773-1774.
58. Sugidachi A, Ogawa T, Kurihara A et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-1551. (Pubitemid 46965386)
59. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk angioplasty. Circulation 1994; 90: 1757-1764.
60. Vincentelli A, Susen S, Le Torneau T et al. Acquires von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349. (Pubitemid 36886240)
61. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation. JAMA 1999; 281: 145-150.
62. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
63. Zotz RB, Scharf RE. Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia. Hämostaseologie 2007; 27: 251-262. (Pubitemid 47612020)